85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-002709-23-DE18/12/202031/01/2020A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 inparticipants with idiopathic pulmonary fibrosisA randomized, double-blind, dose-ranging, placebo-controlled Phase 2aevaluation of the safety, tolerability and pharmacokinetics of PLN-74809 inparticipants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) Idiopathic pulmonary fibrosis (IPF)
MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not Available
Other descriptive name: PLN-74809-000
Pliant Therapeutics Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 2United States;France;Canada;Belgium;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy
2EUCTR2019-002709-23-GB06/11/202024/01/2020A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosisA randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) Idiopathic pulmonary fibrosis (IPF)
MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not Available
Other descriptive name: PLN-74809-000
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not available
Other descriptive name: PLN-74809-000
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not Available
Other descriptive name: PLN-74809-000
Pliant Therapeutics Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;France;Canada;Belgium;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom
3NCT04396756March 3, 20206/5/2020Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)Idiopathic Pulmonary FibrosisDrug: PLN-74809;Drug: PlaceboPliant Therapeutics, Inc.NULLRecruiting40 YearsN/AAll84Phase 2United States;Canada
4NCT04072315September 9, 201923/8/2019Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPF/A Phase 2a Evaluation of PLN-74809 on avß6 Receptor Occupancy Using PET Imaging in Participants With IPFIdiopathic Pulmonary FibrosisDrug: PLN-74809;Drug: Placebo;Radiation: Knottin tracerPliant Therapeutics, Inc.Stanford UniversityRecruiting40 Years80 YearsAll18Phase 2United States